$13MSeed, 6 May 2026
Launch funding advances its APEXm platform and lead in vivo CAR-T program for autoimmune disease.
- Amount
- $13M
- Stage
- Seed
- Announced
- 6 May 2026
- Lead
- Breyer Capital
- Other investors
- General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC
- Use of funds
- Launch funding advances its APEXm platform and lead in vivo CAR-T program for autoimmune disease.
- Checked
- Announced by the company
- Sources
- ParcelBio launches with $13M seed for mRNA medicines businesswire.com
ParcelBio launches with $13M seed for mRNA medicines pulse2.com